(4-aminotetrahydro-2H-pyran-4-yl)acetic acid, 95.0%, 5g

1-(Morpholin-4-yl)-2-(piperazin-1-yl)ethane-1,2-dione, 98%, 250mg

(S)-N-((R)-3,3-Dimethylbutan-2-yl)-3,3-dimethyl-2-(((1-methyl-1H-imidazol-2-yl)methyl)amino)butanamide, 97%, 1g

2-(2-Chloroethyl)-1-methylpiperidine hydrochloride, 10g

2-Bromo-3-methoxybenzoic acid, 95.0%, 10g

GC-Kapillarsäule ROTI®Cap-5, unpolar, L 50 m, Ø-Innen 0,32 mm, Filmd. 0,35 µm, 1 Stück

4,7-Dibromo-5,6-difluoro-2,1,3-benzothiadiazole>98.0%(GC)200mg

1-(4-Fluoro-3-(trifluoromethyl)phenyl)-3-(5-(pyridin-4-yl)-1,3,4-thiadiazol-2-yl)urea, 98+%, 50mg

4,5,6-Trichloropyrimidine, 95.0%, 5g

1-Bromo-2-(bromodifluoromethyl)cyclohexane, 97.0%, 1g

4-Fluoro-o-anisaldehyde>97.0%(GC)5g

1-Bromo-3-(methoxymethyl)benzene, 95.0%, 10g

(S)-Methyl 4-(1-aminoethyl)benzoate hydrochloride, 98.0%, 2.5g